Pharmacotherapy for obesity

Appetite

Volumn 46, Issue 1, 2006, Pages 6-10

  Halford, Jason C G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Appetite; Clinical trials; Drugs; Obesity; Orlistat Xenical; Rimonabant Accompha; Sibutramine; Weight loss

Indexed keywords

PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ABDOMINAL PAIN; ARTICLE; CLINICAL TRIAL; DEFECATION URGENCY; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; FECES; FLATULENCE; HEART PALPITATION; HUMAN; HYPERTENSION; INCIDENCE; INCONTINENCE; OBESITY; SIDE EFFECT; SPOTTING; TACHYCARDIA; VASODILATATION; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; COST OF ILLNESS; CYCLOBUTANES; FOOD HABITS; HUMANS; LACTONES; OBESITY; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 29944438889     PISSN: 01956663     EISSN: 10958304     Source Type: Journal    
DOI: 10.1016/j.appet.2005.07.010     Document Type: Article

References (27)

1. K. Ackroff, and A. Sclafani Effects of the lipase inhibitor orlistat on intake and preference for dietary fats in rats American Journal of Physiology 271 1996 R48 R54
2. D.J. Goldstein Beneficial health effects of modest weight loss International Journal of Obesity 16 1992 397 415
3. R. Guerciolini Mode of action of orlistat International Journal of Obesity 21 1997 S12 S23
4. C.K. Haddock, W.S.C. Poston, P.L. Dill, J.P. Froreyt, and M. Ericsson Pharmacotherapy for obesity: A quantitative analysis of four decades of published randomised clinical trials International Journal of Obesity 26 2002 262 273
5. J.C.G. Halford, T.M. Dovey, and G.D. Cooper Pharmacology of human appetite expression Current Drug Targets 5 2004 211 240
6. D.L. Hansen, S. Toubro, M.J. Stock, I.A. Macdonald, and A. Astrup The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction International Journal of Obesity 23 1999 1016 1024
7. J.B. Hauptman, F.S. Jeunet, and S. Hartmann Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin) American Journal of Clinical Nutrition 55 1992 S309 S322
8. D.J. Heal, A. Aspely, M.R. Prow, H.C. Jackson, K.F. Martin, and S.C. Cheetham Sibutramine: A novel anti-obesity drug. A review of the pharmacological evidence to differentiate from d-amphetamine and d-fenfluramine International Journal of Obesity 22 Suppl. 1 1998 S18 S28
9. H.M. Hesmati, H. Caplain, F. Bellisle, M. Mossé, and C. Fauveau SR141716, a selective cannabinoid CB1 receptor antagonist, reduces hunger, caloric intake and body weight in over weight or obese men Obesity Research 9 S 2001 s71
10. P. Hildebrand, C. Petrig, B. Burckhardt, S. Ketterer, H. Lengsfeld, and A. Fleury Hydrolysis of dietary fat by pancreatic lipase stimulates cholecystokinin release Gasterenterology 114 1998 123 129
11. H.C. Jackson, M.C. Bearham, S.E. Mazurkiewicz, D.J. Heal, and W.R. Bickett Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and nor-adrenaline reuptake inhibitor sibutramine in the rat British Journal of Pharmacology 121 1997 1613 1618
12. W.P.T. James, A. Astrup, N. Finer, J. Hiltes, P. Kopleman, and S. Rossner Effect of sibutramine on weight maintenance after weight loss: A randomised trial Lancet 356 2000 2119 2125
13. S.H. Kim, Y.M. Lee, H.J. Jee, and C.M. Nam Effect of sibutramine on weight loss and blood pressure: A meta-analysis of controlled trials Obesity Research 11 2003 1116 1123
14. B. Mittendorfer, R.E. Ostlund, B.W. Patterson, and S. Klein Orlistat inhibits dietary cholesterol absorption Obesity Research 9 2001 599 603
15. D. O'Donovan, C. Feinle-Bisset, J. Wishart, and M. Horowitz Lipase inhibition attenuates the acute inhibitor effects of oral fat on food intake in healthy subjects The British Journal of Nutrition 90 2003 849 852
16. R. Padwal, S.K. Li, and D.C.W. Lau Long-term pharmacotherapy for overweight and obesity: A systematic review and meta-analysis of randomised control trials International Journal of Obesity 27 2003 1437 1446
17. B.J. Rolls, D.J. Shide, M.L. Thorwart, and J.S. Ulbrecht Sibutramine reduces food intake in non-dieting women with obesity Obesity Research 6 1998 1 11
18. H.M. Seagle, D.H. Bessesen, and J.O. Hill Effect on sibutramine on resting metabolic rate and weight loss in over weight women Obesity Research 6 1998 115 121
19. L. Sjöström, J-P Després, and A. Golay Weight loss in overweight/obese dyslipidemia subjects treated with rimonabant: the RIO-Lipids trial Int. J. Obesity 28 sl 2004 s28
20. L. Sjöström, A. Rissanen, T. Andersen, M. Boldrin, A. Golay, and H.P.F. Kopperchaar Randomised placebo-controlled trial of orlistat for weight loss and prevention of regain in obese patients Lancet 352 1998 167 172
21. M.J. Stock Sibutramine: A review of the pharmacology of a novel anti-obesity agent International Journal of Obesity 21 Suppl. 1 1997 S25 S29
22. A. Swhwizer, K. Asal, C. Kreiss, C. Mettraus, J. Borovicka, and B. Remy Role of lipase in the regulation of upper gastrointestinal function in humans American Journal of Physiology 273 1997 G612 G620
23. J.S. Torgerson, J. Hauptman, M.N. Boldrin, and L. Sjöström XENical in the prevention of diabetes in obese subjects (XENDOS) study. A randomised study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients Diabetes Care 27 2004 155 161
24. A. Ullrich, J. Erdmann, J. Margraf, and A. Schusdziarra Impact of carbohydrate and fat intake on weight-reducing efficacy of orlistat Alimentary Pharmacology and Therapeutics 17 2003 1007 1013
25. H.M. Vidgreen, J.J. Ågren, R.S. Valve, L.J. Karhunen, A.M. Risanen, and M.I.J. Uusitupa The effect of orlistat on the fatty acid composition of seum lipid fractions in obese subjects Clinical Pharmacology and Therapeutics 66 1999 315 322
26. J. Zhi, A.T. Melia, H. Eggers, R. Joly, and I.H. Patel Review of limited systematic absorption orlistat, a lipase inhibitor, in healthy human volunteers Journal of Clinical Pharmacology 35 1995 1103 1108
27. J. Zhi, T.E. Mulligan, and J.B. Hauptman Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients Journal of Clinical Pharmacology 39 1999 41 46